Update
$bluebird bio(BLUE.US$ bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital -
- 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 -
- First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid -
- 62 qualified treatment centers (QTCs) activated -
- Full year 2023 revenue of $29.5 million with $7.8 million generated in the fourth quarter -
- Management to host conference call today, March 26, 2024 at 8:00 am ET -
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital -
- 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient starts anticipated across the portfolio in 2024 -
- First government outcomes-based agreement for sickle cell disease signed with Michigan Medicaid -
- 62 qualified treatment centers (QTCs) activated -
- Full year 2023 revenue of $29.5 million with $7.8 million generated in the fourth quarter -
- Management to host conference call today, March 26, 2024 at 8:00 am ET -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
